A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
← catalyst calendarSponsored by Corvus Pharmaceuticals, Inc. (industry) · CRVS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
151estimated
Sites
22
Countries
Australia, China, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-05-03 | actual | When the study began enrolling |
| Primary completion | 2026-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- T-cell Lymphoma
Intervention
- Drug: CPI-818
Primary outcomes
what the primary-completion date above is the date OFIncidence, nature, and severity of adverse events following treatment with CPI 818 to establish the safety and tolerability with increasing dose
measured First dose until 30 days after treatment stop
Incidence and nature of dose limiting toxicities (DLTs) of CPI 818 to establish either the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of CPI 818
measured Up to approximately 21 days after first dose
Permalink · CRVS's whole pipeline · Catalyst calendar · Every registered study · What changed